Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.

Demcizumab (0-100 μg/mL) 结合人 DLL4 但不结合鼠 DLL4，并在 FACS 结合测定中阻断 DLL4 与 Notch1 受体的结合。
Demcizumab (20 μg/mL，48 小时) 降低 PDTALL 细胞中的 HES1 和 DTX1 mRNA 表达^[4]。
Demcizumab (0-80 μg/mL，1 或 2 或 3 天) 促进 PDTALL13 细胞死亡和早期凋亡^[4]。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Demcizumab (10 mg/kg，i.p.，每周一次) 联合 Irinotecan (7.5 mg/kg) 在 KRAS^WT 和 KRAS^MT CRC 异种移植模型中显示出显着的抗肿瘤作用.
Demcizumab 单独或与伊立替康 (7.5 mg/kg) 联合使用对 OMP-C8 结肠肿瘤有效。
Demcizumab (20 mg/kg/周，腹腔注射) 增加注射了 PDTALL13 细胞的受辐照 NRG 小鼠的存活率^[4]。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Demcizumab (10 mg/kg，i.p.，每周一次) 联合 Irinotecan (7.5 mg/kg) 在 KRAS^WT 和 KRAS^MT CRC 异种移植模型中显示出显着的抗肿瘤作用.
Demcizumab 单独或与伊立替康 (7.5 mg/kg) 联合使用对 OMP-C8 结肠肿瘤有效。
Demcizumab (20 mg/kg/周，腹腔注射) 增加注射了 PDTALL13 细胞的受辐照 NRG 小鼠的存活率^[4]。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303.  [Content Brief]

  . Fischer M, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011;71:1520-5.  [Content Brief]

  . Hoey T, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168–77.  [Content Brief]

  [4]. Xiong H, et al. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics. 2021 Jan 1;11(4):1594-1608.  [Content Brief]